NCT04808414View on ClinicalTrials.gov

SAD/MAD Safety and PK Study of QPX9003 (Novel Polymyxin) in Normal Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

104

Participants

Timeline

Start Date

June 3, 2021

Primary Completion Date

July 14, 2022

Study Completion Date

July 14, 2022

Conditions
Bacterial Infections
Interventions
DRUG

QPX9003 for IV Infusion

antibiotic

DRUG

Placebo for IV infusion

Placebo comparator

Trial Locations (1)

90630

Altasciences, Cypress

All Listed Sponsors
collaborator

Biomedical Advanced Research and Development Authority

FED

lead

Qpex Biopharma, Inc.

INDUSTRY